Treatment with the TGF-β signaling inhibitor A8301 as well as ZEB1 knockdown prevented the acquisition of mesenchymal marker expression and morphological changes, thus linking mesenchymal differentiation in GBM with enhanced tumor cell invasion through the TGF-β–ZEB1 axis. Here, TGFB1 is linked to glioblastoma.